HK Stock Market Move | LEADS BIOLABS-B(09887) rose by more than 4%, the first-line treatment of bile duct cancer stage II study of Velixxin has successfully entered the expansion stage.

LEADS BIOLABS-B(09887) surged more than 4%, as of press time, it rose 4.39% to HK$93.9, with a turnover of HK$13.3778 million. In terms of news, on April 8th, Vetsun Pharma announced that the Phase II clinical trial of the company's independently developed PD-L1/4-1BB bispecific antibody VELISIN (LBL-024) for the first-line treatment of advanced biliary tract cancer has completed the preliminary evaluation of safety. Based on good safety and encouraging efficacy data, the project has successfully entered the expansion phase, and the first patient has been recruited. Data shows that VELISIN combined with chemotherapy has good overall safety and tolerability, with no new safety signals identified; preliminary efficacy assessment shows a promising trend of tumor shrinkage. Based on good safety and encouraging efficacy data, the project has smoothly entered the expansion phase and is accelerating progress.